Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Peri-aortic fat to assess cardiovascular aging using an AI-driven radiomic biomarker.

European heart journal·2026

Same author

Development and Validation of a Computational Histology Artificial Intelligence-Powered Biomarker in Metastatic Hormone-Sensitive Prostate Cancer on Randomized Phase III Trials.

JCO precision oncology·2026

Same author

Participant Heterogeneity in the Prostate Cancer Biobank of the NRG: An Obstacle to Broadening the Reach of Precision Oncology.

JCO precision oncology·2026

Same author

CAR T Cells Targeting O-Glycosylated Fibronectin Exhibit Potent Cytolytic Activity and Combine with Tumoral Toll-Like Receptor Agonism to Overcome Tumor Resistance.

Cancer immunology research·2026

Same author

Single-cell transcriptomic analysis reveals tumor-immune determinants of lymph node colonization and progression in thyroid cancer.

Science advances·2026

Same author

A Multimodal Artificial Intelligence Model to Guide Use of Whole-Pelvic Radiation Therapy in Patients with Localized Prostate Cancer: Exploratory Analysis of RTOG 9413.

Cancers·2026

Search research articles

Related Experiment Video

Updated: Jun 14, 2026

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

A Computational Pathology Model to Predict Docetaxel Benefit in Localized High-Risk and Metastatic Prostate Cancer.

Sebastian Medina¹, Naoto Tokuyama¹, Kamal Hammouda^1,2,3

¹The Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University, Atlanta, Georgia.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research

|December 1, 2025

Summary

An artificial intelligence-based pathology image classifier (APIC) can predict which prostate cancer patients will benefit from docetaxel chemotherapy. This AI tool helps personalize treatment by identifying patients likely to experience improved survival and delayed resistance.

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Predictive Immune Modeling of Solid Tumors

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

Related Experiment Videos

Last Updated: Jun 14, 2026

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Predictive Immune Modeling of Solid Tumors

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

Area of Science:

Oncology
Pathology
Artificial Intelligence

Background:

Docetaxel improves survival in metastatic hormone-sensitive prostate cancer (mHSPC) and high-risk localized prostate cancer.
Patient benefit from docetaxel varies, necessitating predictive biomarkers to avoid toxicity in non-responders.

Purpose of the Study:

To develop and validate an artificial intelligence-based pathology image classifier (APIC) for predicting docetaxel benefit in prostate cancer patients.
To identify patients who will benefit from docetaxel, thereby optimizing treatment strategies and minimizing toxicity.

Main Methods:

Digitized H&E-stained biopsy specimens from two phase 3 trials (CHAARTED and NRG/RTOG 0521) were analyzed.
APIC utilized features capturing tumor-immune spatial interactions and nuclear heterogeneity.
The predictive value of APIC for docetaxel benefit on overall survival and castration-resistance was evaluated using Cox proportional hazards models.

Main Results:

APIC-positive patients in the CHAARTED trial showed significant overall survival improvement (HR 0.52) and delayed castration-resistance (HR 0.48) with docetaxel.
APIC-negative patients in CHAARTED showed no significant benefit from docetaxel (HR 1.31).
Similar significant predictive value was observed in the NRG/RTOG 0521 trial, with APIC-positive patients demonstrating survival benefit (HR 0.49).

Conclusions:

APIC effectively predicts docetaxel benefit in both metastatic and localized prostate cancer, independent of clinical factors.
This AI-driven approach can guide treatment decisions for docetaxel therapy.
Further validation in triplet therapy regimens is warranted.